Oxford BioMedica (OXOA) Stock Statistics & Valuation Metrics
Total Valuation
Oxford BioMedica has a market cap or net worth of EUR 779.85M. The enterprise value is EUR 838.44M.
- Market Cap
- EUR 779.85M
- Enterprise Value
- EUR 838.44M
Share Statistics
Oxford BioMedica has 121,050,156 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 121,050,156
- Owned by Insiders
- 0.38%
- Owned by Institutions
- 4.56%
Financial Efficiency
Oxford BioMedica’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -11.48%.
- Return on Equity (ROE)
- -0.33
- Return on Assets (ROA)
- -0.09
- Return on Invested Capital (ROIC)
- -11.48%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 165.92K
- Profits Per Employee
- -29.62K
- Employee Count
- 1,017
- Asset Turnover
- 0.52
- Inventory Turnover
- 5.93
Valuation Ratios
The current PE Ratio of Oxford BioMedica is -15.60. Oxford BioMedica’s PEG ratio is 2.20.
- PE Ratio
- -15.60
- PS Ratio
- 3.72
- PB Ratio
- 11.23
- Price to FCF
- -17.98
- Price to Operating Cash Flow
- -24.94
- PEG Ratio
- 2.20
Income Statement
In the last 12 months, Oxford BioMedica had revenue of 168.74M and earned -30.13M in profits. Earnings per share was -0.27.
- Revenue
- 168.74M
- Gross Profit
- 65.98M
- Operating Income
- -29.61M
- Pretax Income
- -31.94M
- Net Income
- -30.13M
- EBITDA
- -9.12M
- Earnings Per Share (EPS)
- -0.27
Cash Flow
In the last 12 months, operating cash flow was -26.15M and capital expenditures -10.15M, giving a free cash flow of -36.30M billion.
- Operating Cash Flow
- -26.15M
- Free Cash Flow
- -36.30M
- Free Cash Flow per Share
- -0.30
Dividends & Yields
Oxford BioMedica pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -5.56%
- Earnings Yield
- -6.24%
Stock Price Statistics
- Beta
- 0.49
- 52-Week Price Change
- -13.61%
- 50-Day Moving Average
- 5.72
- 200-Day Moving Average
- 6.83
- Relative Strength Index (RSI)
- 61.65
- Average Volume (3m)
- 1,844
Important Dates
Oxford BioMedica upcoming earnings date is Apr 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 22, 2026
- Next Earnings Date
- Apr 15, 2027
- Ex-Dividend Date
- ―
Financial Position
Oxford BioMedica as a current ratio of 2.20, with Debt / Equity ratio of 162.16%
- Current Ratio
- 2.20
- Quick Ratio
- 2.00
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- -5.62
- Interest Coverage Ratio
- -2.14
Taxes
In the past 12 months, Oxford BioMedica has paid -1.29M in taxes.
- Income Tax
- -1.29M
- Effective Tax Rate
- 0.04
Enterprise Valuation
Oxford BioMedica EV to EBITDA ratio is -53.59, with an EV/FCF ratio of -20.27.
- EV to Sales
- 4.20
- EV to EBITDA
- -53.59
- EV to Free Cash Flow
- -20.27
- EV to Operating Cash Flow
- -28.14
Balance Sheet
Oxford BioMedica has EUR 75.28M in cash and marketable securities with EUR 158.64M in debt, giving a net cash position of -EUR 83.36M billion.
- Cash & Marketable Securities
- EUR 75.28M
- Total Debt
- EUR 158.64M
- Net Cash
- -EUR 83.36M
- Net Cash Per Share
- -EUR 0.69
- Tangible Book Value Per Share
- EUR 0.28
Margins
Gross margin is 36.03%, with operating margin of -15.71%, and net profit margin of -23.23%.
- Gross Margin
- 36.03%
- Operating Margin
- -15.71%
- Pretax Margin
- -24.02%
- Net Profit Margin
- -23.23%
- EBITDA Margin
- -7.83%
- EBIT Margin
- -18.52%
Analyst Forecast
The average price target for Oxford BioMedica is EUR 9.24, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 9.24
- Price Target Upside
- 45.56% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- 12.13%
- EPS Growth Forecast
- 6.62%